Skip to main content

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Merck, DuPont, and More

Premium

Title: Method and Substances for Isolating miRNAs

Patent Number: 8,524,448

Filed: Aug. 29, 2012

Lead Inventor: Elliott Dawson, Bioventures

The invention, the patent's abstract states, comprises "a capture probe suitable for use with a method for isolating miRNAs."


Title: In Vivo Delivery of Double-stranded RNA to a Target Cell

Patent Number: 8,524,679

Filed: Nov. 6, 2007

Inventor: Catherine Pachuk, Veritas Bio

"The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell … [and] the first cell facilitates delivery of the dsRNA to the target cell," the patent's abstract states.


Title: High-potency siRNAs for Reducing the Expression of Target Genes

Patent Number: 8,524,680

Filed: Aug. 31, 2009

Lead Inventor: David Brown, Applied Biosystems

The invention, the patent's abstract states, "provides improved methods of attenuating gene expression through the phenomenon of RNA interference. The invention provides methods of synthesis of double-stranded RNAs of increased potency for use as small interfering RNA."


Title: siRNA Sequence-independent Modification Formats for Reducing Off-target Phenotypic Effects in RNA, and Stabilized Forms Thereof

Patent Number: 8,524,681

Filed: March 19, 2010

Lead Inventor: Nitin Puri, Applied Biosystems

The invention comprises "modification formats having modified nucleotides … for siRNA," the patent's abstract states. "Short interfering RNA having modification formats and modified nucleotides provided herein reduce off-target effects in RNA interference of endogenous genes. Further modification-formatted siRNAs are demonstrated to be stabilized to nuclease-rich environments."


Title: RNAi Molecule Targeting Thymidylate Synthase and Application Thereof

Patent Number: 8,524,876

Filed: March 29, 2010

Lead Inventor: Hiromi Wada, Delta-Fly Pharma

"This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-[fluorouracil] antitumor agent," the patent's abstract states.


Title: RNA Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof

Patent Number: 8,524,879

Filed: May 5, 2010

Lead Inventor: Beverly Davidson, University of Iowa

The invention, the patent's abstract states, "is directed to small interfering RNA molecules targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules."


Title: Reduction of Off-target RNA Interference Toxicity

Patent Number: 8,524,881

Filed: July 18, 2012

Lead Inventor: Beverly Davidson, University of Iowa

The invention is directed to "RNA interference molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity," the patent's abstract states.


Title: Downregulation of Gene Expression Using Artificial microRNAs for Silencing Fatty Acid Biosynthetic Genes

Application Number: 20130219565

Filed: Jan. 23, 2013

Lead Inventor: Howard Glenn Damude, DuPont

The invention, the patent application's abstract, states, relates to "isolated nucleic acid fragments comprising precursor miRNAs, and artificial miRNAs and their use in downregulating gene expression of fatty acid biosynthetic genes."


Title: Inhibition of Nonsense-mediated Decay Pathways

Application Number: 20130224237

Filed: July 20, 2011

Inventor: Eli Gilboa, University of Miami

The patent application, its abstract states, claims "compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense-mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases."


Title: siRNA Targeting Apolipoprotein B

Application Number: 20130225447

Filed: April 22, 2013

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for ApoB."


Title: siRNA Compositions and Methods for Potently Inhibiting Viral Infection

Application Number: 20130225651

Filed: Dec. 12, 2011

Lead Inventor: Bojiian Zheng, University of Hong Kong

The patent application, its abstract states, claims prophylactic and therapeutic siRNA agents useful against H5N1 influenza virus, as well as "other viral infections."


Title: Segmented microRNA Mimetics

Application Number: 20130225652

Filed: Aug. 24, 2010

Lead Inventor: Guillaume Chorn, Merck

"This invention relates generally to segmented oligonucleotides capable of modulating gene expression," the patent application's abstract states. "Specifically, the … invention relates to segmented microRNA oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA."


Title: microRNA-based Short Hairpin RNA for Gene Knockdown of NR1 Subunit of N-Methyl-D-Aspartate Receptor and Its Application of Pharmaceutics

Application Number: 20130225653

Filed: July 10, 2012

Inventor: Ping-Heng Tan, Chinese Academy of Sciences

The invention relates to a "microRNA-based short hairpin RNA for gene silencing the genetic expression of NR1 subunit of N-methyl-D-aspartate receptor," the patent application's abstract states.


Title: Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

Application Number: 20130225654

Filed: Sept. 26, 2012

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus," the patent application's abstract states.


Title: siRNA Targeting ETS1 and ELK1 and Method of Using Same in the Inhibition of CIP2A Gene in Cancer Treatment

Application Number: 20130225657

Filed: Feb. 26, 2013

Lead Inventor: Lyndi Rice, Medical Diagnostic Laboratories

The patent application, its abstract states, claims "methods of attenuating activity of the gene promoter of CIP2A … [using] siRNAs … to target against Ets1 and Elk1 transcriptional factors, thereby blocking the binding of Ets1 and Elk1 to the CIP2A gene promoter. It is disclosed that the siRNAs targeted against Ets1 and Elk1 attenuate the gene expression of CIP2A. A kit containing siRNA reagents for attenuating the CIP2A gene expression is also disclosed."


Titles: microRNAs that Regulate Muscle Cell Proliferation and Differentiation

Application Numbers: 20130225658, 20130225665

Filed: March 8, 2013

Lead Inventor: Da-Zhi Wang, University of North Carolina at Chapel Hill

The invention comprises "methods and compositions for modulating gene expression in myocytes," the patent applications' abstracts states.


Title: Lipid Delivery Formulations

Application Number: 20130225663

Filed: Aug. 27, 2012

Inventor: Bob Brown, Dicerna Pharmaceuticals

"The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response [that] would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid," the patent application's abstract states. "Specific immune response reducing lipids and uses thereof are further provided."


Title: siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B

Application Number: 20130225667

Filed: April 22, 2013

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B."

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.